Impairing the Phagocytic Capacity of MPS

To avoid the accumulation of the injected particles in the MPS organs, strategies were developed in the early 1980s to impair the phagocytic capacity of macrophages in contact with blood, for example, by injecting large doses of placebo carriers before the administration of the drug loaded carriers [11, 12]. However, these approaches have the inconvenience to impair or to suppress the essential defense system of the body and can have serious consequences, especially in cancer patients. Preferred strategies are particle camouflage from MPS, for example, by modifying their surface to make it "stealth" toward phagocytic cells. For this, surface-engineered nanoparticles have been conceived by taking into account the interactions between the carriers and blood components.

0 0

Post a comment